By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Peregrine Pharmaceuticals, Inc. 

14272 Franklin Avenue, Suite 100

Tustin  California  92780  U.S.A.
Phone: 714-508-6000 Fax: 714-838-5817



AVANIR Pharmaceuticals 

Company News
Peregrine Pharmaceuticals, Inc. (PPHM) Reports Fourth Quarter And Year-End Fiscal Year 2015 Financial Results And Recent Developments 7/15/2015 7:18:58 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 6/5/2015 7:31:06 AM
ASCO15: Data Presentations At ASCO Demonstrate The Ability Of Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab To Activate Tumor Targeting Immune Cells In PD-L1 Negative NSCLC Tumors 6/1/2015 8:52:42 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Provides Update On Planned Expansion Of Bavituximab Clinical Program 6/1/2015 8:14:36 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Enters Into Research Collaboration To Investigate Novel PS-Targeting Immunotherapy Combinations 5/29/2015 8:51:41 AM
ASCO15: Peregrine Pharmaceuticals, Inc. (PPHM) Announces Webcast Of Immunotherapy Roundtable At ASCO Annual Meeting 5/28/2015 7:24:35 AM
Peregrine Pharmaceuticals, Inc. (PPHM)' Immuno-Oncology Agent Bavituximab To Be Highlighted In Three Presentations At 2015 ASCO Annual Meeting 5/14/2015 10:44:11 AM
Preclinical Data Presented At AACR Demonstrate Synergistic Anti-Tumor Effects Of Peregrine Pharmaceuticals, Inc. (PPHM)'s Phosphatidylserine (PS)-Targeting Antibodies With Immune Checkpoint Inhibitors In Models Of Melanoma And Breast Cancer 4/21/2015 8:04:09 AM
Data Presented At AACR Demonstrate Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab Induces Immune Activation In PD-L1 Negative NSCLC Tumors 4/20/2015 8:28:55 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Three Abstracts Accepted For Presentation At American Association for Cancer Research 2015 Annual Meeting 4/15/2015 4:02:59 PM